TITLE

Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study

AUTHOR(S)
T T Seppälä
PUB. DATE
October 2010
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Oct2010, Vol. 81 Issue 10, p1123
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Single measurements of plasma Aβ are not useful in the diagnostics of Alzheimer's disease (AD). However, changes in plasma Aβ levels during repeated testing may be helpful in the prediction and evaluation of progression of the incipient AD or mild cognitive impairment. OBJECTIVE: To examine the relation of baseline and serial plasma Aβ levels to cognitive change in follow-up. METHODS: 269 subjects (52 cognitively impaired and 217 controls) from a population-based cohort were clinically followed up from 3 to 6 years. Serial plasma samples were available from 70 subjects who were followed up for 3 years and 43 subjects followed for 6 years. The plasma Aβ levels were measured using ELISA. RESULTS: Subjects who declined cognitively during the follow-up had lower levels of plasma Aβ42 at the baseline. Plasma Aβ42 and the Aβ42/Aβ40 ratio decreased (–2.4 pg/ml for Aβ42 in 6 years) in those who declined in follow-up, whereas Aβ42 and the Aβ42/Aβ40 ratio increased in the subjects who remained cognitively stable or improved in follow-up. Subjects using acetylsalicylic acid, dipyridamole, antidiabetic or anticoagulant drugs as well as subjects with coronary heart disease had higher levels of Aβ40. CONCLUSIONS: Low or decreasing plasma Aβ42 during the follow-up is associated with cognitive decline. Serial measurement of plasma Aβ42 may be useful in the detection of the subjects who are at risk for cognitive decline.
ACCESSION #
54245470

 

Related Articles

  • Long-term dual antiplatelet therapy appropriate after PCI.  // Geriatrics;Jan2003, Vol. 58 Issue 1, p61 

    Highlights the multicenter Clipidogrel for the Reduction of Events During Observation trial, led by Steven R. Steinhubl, which found a need for patients who undergo an elective percutaneous coronary intervention procedure to continue on dual antiplatelet therapy with clopidogrel and aspirin for...

  • Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Kelly, R. V.; Sleinhubi, S. // Heart;Jun2005 Supplement 3, Vol. 91, piii16 

    The article focuses on the changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention (PCI). Antiplatelet and anticoagulant treatments are essential in the management of PCI patients. Aspirin should be given to all patients and likely maintained...

  • The WOEST Trial: First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde, Willem; Oirbans, Tom; Verheugt, Freek; Kelder, Johannes; De Smet, Bart; Herrman, Jean-Paul; Adriaenssens, Tom; Vrolix, Mathias; Heestermans, Antonius; Vis, Marije; Rasoul, Saman; Sheikjoesoef, Kaioum; Vandendriessche, Tom; Van Mieghem, Carlos; Cornelis, Kristoff; Vos, Jeroen; Brueren, Guus; Breet, Nicolien; Berg, Jurri�n ten // Cardiologia Croatica;2012, Vol. 7 Issue 9/10, Special section p1 

    The article provides information on the WOEST Trial which compared two regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stenting. It outlines the study designs. The background and limitations of the study are mentioned. It concludes that the...

  • Triple therapy (aspirin, Clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine. Tanrıkulu, Azra; Ağırbaşlı, Mehmet // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Aug2013, Vol. 13 Issue 5, p486 

    Studies indicate that 5-7% patients undergoing percutaneous coronary intervention (PCI) have an indication for anticoagulation therapy. Most commonly atrial fibrillation (AF) is the indication. These subjects require triple therapy with aspirin, Clopidogrel, and an oral antico-agulant (OAC)....

  • Risk of death in abrupt clopidogrel cessation. Praities, Nigel // Pulse;2/13/2008, Vol. 68 Issue 5, p10 

    The article focuses on the issue concerning the adverse effect of abrupt cessation in using clopidogrel, a potent oral antiplatelet agent used in treating coronary artery disease. It reports that patients who are abruptly taken off clopidogrel are vulnerable to risk of a myocardial infarction or...

  • Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence. Tourmousoglou, C. E.; Rokkas, C. K. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 4, p312 

    Dual antiplatelet therapy represents an important advance for patients with established coronary artery disease. It is an important strategy for patients with acute coronary syndromes and those undergoing percutaneous transcatheter coronary interventions. Clopidogrel effectively inhibits...

  • Warfarin, Aspirin, or Both after Myocardial Infarction. Hurlen, Mette; Abdelnoor, Michael; Smith, Pål; Erikssen, Jan; Arnesen, Harald // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p969 

    Background: The role of antithrombotic therapy in secondary prevention after myocardial infarction is well established. Although the available literature suggests that warfarin is superior to aspirin, aspirin is currently the more widely used drug. We studied the efficacy and safety of warfarin,...

  • Aspirin + clopidogrel therapy: How does your care compare to the evidence? Simmons, B. Brent; Salzman, Brooke E. // Journal of Family Practice;Jan2008, Vol. 57 Issue 1, p26 

    The article focuses on the latest trials and recommendations on dual antiplatelet therapy as they pertain to acute coronary syndrome (ACS), coronary stents, stroke, and the primary prevention and secondary prevention of distant cardiovascular events. One of the trials cited is The Clopidogrel in...

  • Aspirin Combined With Clopidogrel (Plavix) Decreases Cardiovascular Events in Patients with Acute Coronary Syndrome. Walker, Christopher W.; Dawley, Courtney A.; Fletcher, Stacy F. // American Family Physician;12/1/2007, Vol. 76 Issue 11, p1643 

    The article focuses on the effectiveness of the combination of aspirin with clopidogrel in treating patients with a high risk of cardiovascular disease or patients with acute coronary syndrome. It notes that clopidogrel improves outcomes in patients with coronary artery stent replacement....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics